Beam Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Beam Therapeutics Inc.
The company sees its gene-editing technology, which it compares to a DNA “word processor,” as having potentially broad applicability.
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.
Lilly brings challenger Natco into licensee fold for baricitinib in COVID-19, while the Indian firm retracts a compulsory licensing application for the JAK inhibitor, rapidly diffusing a potentially difficult situation for both sides. But will the six other baricitinib licensees in India match the price of Natco’s on-market version?
Cell, gene and RNA therapies are starting to transform the healthcare landscape and a report from the American Society of Gene + Cell Therapy and Informa Pharma Intelligence maps the progress the sector made in the first quarter of 2021.
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Guide Therapeutics, Inc.